Literature DB >> 24847190

Cellular Stress Induced by Plasma-Derived Factor VIII Products.

Martin Brodde1, Anja Müller1, Beate Kehrel2.   

Abstract

BACKGROUND: We previously identified protein impurities in plasma-derived factor VIII (pdFVIII) products. The goal of the current experiments was to determine whether these impurities might have clinical relevance, by comparing the effects of pdFVIII and recombinant FVIII (rFVIII) products on cellular stress induction.
METHODS: The in vitro outcomes on cell stress sensors of 2 pdFVIII products and 1 rFVIII product were evaluated. Microparticle formation was assessed in cells treated with the 3 products. Effects on the mitochondrial membrane potential were measured in cells treated with clinically relevant concentrations of each product.
RESULTS: Microparticle formation was induced in platelets by 1 pdFVIII product and in monocytes and granulocytes by both pdFVIII products; the rFVIII product did not affect microparticle formation. Both pdFVIII products, but not the rFVIII product, significantly depolarized the mitochondrial membrane potential.
CONCLUSION: The 2 pdFVIII products tested induced cellular stress in in vitro experiments. No such results were seen with the rFVIII product. Chronic activation of the cell stress defense system and chronic cell irritation may have clinical consequences for patients with hemophilia A.

Entities:  

Keywords:  Cell stress; Factor VIII; Hemophilia; Plasma derived; Recombinant

Year:  2014        PMID: 24847190      PMCID: PMC4025058          DOI: 10.1159/000357992

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  21 in total

Review 1.  Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death.

Authors:  M R Duchen
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

2.  HMEC-1: establishment of an immortalized human microvascular endothelial cell line.

Authors:  E W Ades; F J Candal; R A Swerlick; V G George; S Summers; D C Bosse; T J Lawley
Journal:  J Invest Dermatol       Date:  1992-12       Impact factor: 8.551

Review 3.  The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases.

Authors:  Paolo Puddu; Giovanni M Puddu; Eleonora Cravero; Silvia Muscari; Antonio Muscari
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

Review 4.  Mitochondrial membrane permeabilization in cell death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Catherine Brenner
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 5.  Plasma microparticles and vascular disorders.

Authors:  Susan F Lynch; Christopher A Ludlam
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

6.  Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore.

Authors:  Valery Leytin; David J Allen; Asuman Mutlu; Armen V Gyulkhandanyan; Sergiy Mykhaylov; John Freedman
Journal:  Lab Invest       Date:  2009-02-23       Impact factor: 5.662

7.  In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

Authors:  V Combes; A C Simon; G E Grau; D Arnoux; L Camoin; F Sabatier; M Mutin; M Sanmarco; J Sampol; F Dignat-George
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

8.  Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease.

Authors:  Nikos Werner; Sven Wassmann; Patrick Ahlers; Sonja Kosiol; Georg Nickenig
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-20       Impact factor: 8.311

9.  Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.

Authors:  James G Clifton; Feilei Huang; Spomenka Kovac; Xinli Yang; Douglas C Hixson; Djuro Josic
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

Review 10.  Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.

Authors:  Robert Musso
Journal:  Drugs Today (Barc)       Date:  2008-10       Impact factor: 2.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.